Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma

You may be eligible if

• A history of pathologically documented (clinical documentation may be acceptable at relapse):
• Breast cancer: metastatic or locally advanced (Stage III/IV) with stable minimal (less than or equal to 2 cm) residual disease after 2 cycles of appropriate combination chemotherapy may start BMT.
• Non-Hodgkin's lymphomas: all stages of relapsed or induction failure (FSC, FM, FL, DSC, DL, DM, DIDL, IBL, LBL, SNC) after appropriate chemotherapy.
• Hodgkin's lymphomas: all stages of chemotherapy induction failures, first relapse less than or equal to 1 year from chemotherapy induced remission, first relapse greater than 1 year from chemotherapy induced remission if there is extranodal involvement at relapse, greater than or equal to 2 relapses (one may be after radiation) following appropriate combination chemotherapy, or relapse at any time from radiation therapy with stage IIB, IIIB, IV A/B.
• Testicular cancer: all stages of relapsed or induction failure following appropriate combination chemotherapy.
• No evidence of central nervous system cancer.
• Patients must be between 18 and 65 years old.
• Normal cardiac function: no history of angina pectoris, myocardial infarction, congestive heart failure or ejection fraction less than 40 percent.
• Creatinine clearance greater than or equal to 45 cc/min/m(2), bilirubin less than or equal to 1.5, SGOT less than or equal to 2x normal, and normal PT, PTT and calcium.
• Negative HIV serology and hepatitis B surface antigen.
• Adequate pulmonary function (PFTs are only obtained in patients with clinical evidence of pulmonary dysfunction): DLCO greater than 50 percent, compensated for Hgb, FEV 1 greater than 55 percent and PO2 greater than 60.
• Negative bilateral bone marrow biopsies prior to bone marrow harvest.
• No evidence of metastatic disease to the pelvis on plain film or bone scan.
• Karnofsky performance status greater than or equal to 70 and a life expectancy greater than or equal to 60 days.
• No evidence of pregnancy or risk of pregnancy at the time of transplantation in women.
• Ability to give informed consent.
• Good psychiatric and medical risk.